文献速递骨肿瘤关节外科创伤骨科

简洁的患者报告结局测量工具能否为下肢手术后癌症患者提供有效的身体功能测量

Does a Concise Patient-reported Outcome Measure Provide a Valid Measure of Physical Function for Cancer Patients After Lower Extremity Surgery?
PubMed 文献 · Clin Orthop Relat Res · 2024-10-04

本研究基于单一机构纵向数据库,从TESS LE和LEFS的50个条目中筛选出14个高区分度条目,构建简洁工具LEO。14条目工具对TESS LE的灵敏度96%、特异度90%,对LEFS的灵敏度95%、特异度86%,与原始量表反应性相似。

要点

  • 从TESS LE和LEFS的50个条目中筛选出14个高区分度条目,命名为LEO。
  • 14条目工具对TESS LE的灵敏度96%、特异度90%,AUC为0.98(p < 0.001)。
  • 14条目工具对LEFS的灵敏度95%、特异度86%,AUC为0.96。

核心结论

  • 从TESS LE和LEFS的患者报告反应中得出的14个简洁条目,对因肿瘤和非肿瘤适应症接受下肢骨科手术的癌症患者,显示出与原始TESS LE和LEFS相似的反应性(灵敏度和特异度)。
  • 这14个条目在描述骨科肿瘤患者广泛下肢功能范围方面与TESS LE和LEFS能力相似,且比TESS LE和LEFS合并的50个条目更简短。
  • 这14个条目工具被命名为下肢肿瘤功能评估工具(LEO)。

研究设计与样本

  • 功能结局数据收集并维护于单一机构的纵向维护数据库中。
  • 患者纳入条件为:(1)因影响下肢功能的骨或软组织肿瘤接受肿瘤切除或非肿瘤骨科手术(例如骨关节炎的关节置换术),且(2)在至少两次门诊就诊时完成了LEFS、TESS LE和PROMIS全球健康工具。
  • 2014年9月至2022年4月间,治疗了14234例原发性骨或软组织肉瘤、骨转移性疾病或慢性癌症治疗的骨科后遗症患者。
  • 约6%(854/14234)因需要语言翻译被排除;约2%(278/13380)拒绝或无法参与;72%(9433/13102)的患者接受了下肢手术。
  • 这些患者中4%(339/9433)在≥2次门诊就诊时完成了TESS LE、LEFS和PROMIS全球健康工具第3项。

主要发现

  • 14条目简表、TESS LE和LEFS对PROMIS全球健康工具(第3项)标准目标的反应性(灵敏度和特异度)相似,ROC曲线的曲线下面积(AUC)范围为0.62至0.65。
  • 14条目工具对TESS LE的反应性显示灵敏度96%、特异度90%,AUC为0.98(p < 0.001)。
  • 14条目工具对LEFS的反应性显示灵敏度95%、特异度86%,AUC为0.96。
  • 14条目工具对TESS LE的效度通过一致性测量,精确度为0.98、准确度为0.97。
  • 14条目工具对LEFS的一致性显示精确度为0.98、准确度为0.83。

关键数值与推荐

  • 14条目工具对TESS LE:灵敏度96%、特异度90%,AUC 0.98(p < 0.001)。
  • 14条目工具对LEFS:灵敏度95%、特异度86%,AUC 0.96。
  • 14条目工具对TESS LE的一致性:精确度0.98、准确度0.97。
  • 14条目工具对LEFS的一致性:精确度0.98、准确度0.83。
  • 14条目简表、TESS LE和LEFS对PROMIS全球健康工具第3项的AUC范围为0.62至0.65。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current functional assessment tools for orthopaedic oncology are long surveys that contribute to patients' survey fatigue and yet lack the ability to discern meaningful differences in a patient population that is often mobile but unable to perform strenuous activities. We sought to determine whether a shorter, novel tool based on existing, validated surveys could better capture differences in a sample of orthopaedic oncology patients. QUESTIONS/PURPOSES: (1) Can a concise fixed-item functional tool derived from the 50 items in the Toronto Extremity Salvage Score for the lower extremity (TESS LE) and the Lower Extremity Functional Scale (LEFS) demonstrate similar responsiveness in terms of sensitivity and specificity? (2) What is the precision and accuracy of the concise tool compared with the TESS LE and LEFS? METHODS: Functional outcome data were collected and maintained in a longitudinally maintained database at a single institution. Patients were included in the study if (1) they had undergone a tumor excision or a nononcologic orthopaedic procedure (for example, arthroplasty for osteoarthritis) for a bone or soft tissue tumor affecting lower extremity function, and (2) they had completed the LEFS, TESS LE, and Patient-Reported Outcomes Measurement Information System (PROMIS) global health tool on at least two clinic visits. Between September 2014 and April 2022, we treated 14,234 patients for primary bone or soft tissue sarcoma, metastatic disease to bone, or orthopaedic sequelae of chronic cancer care. Approximately 6% (854 of 14,234) were excluded due to the need of a language translator. Approximately 2% (278 of 13,380) refused or were unable to participate. Seventy-two percent (9433 of 13,102) of the patients had an operation on a lower extremity. Of these, 4% (339 of 9433) of the patients completed the TESS LE, LEFS, and Item 3 of the PROMIS global health tool on ≥ 2 clinic visits. Of the patients in the current study, 49% (167 of 339) were women, and 27% (93 of 339) had metastatic carcinoma. Twelve percent (41 of 339) of the patients died before the end of the study period. Spearman rank-order correlation, principal component analysis (PCA), and item response theory (IRT) modeling identified 14 highly discriminating items from the TESS LE and LEFS. Multiple linear stepwise regression (MLSR) was performed with the dependent variable being the summary score of the 14 items derived from the TESS LE and LEFS and standardized to a percentage of 100. The beta coefficient from the MLSR was used to derive a weight for each of the 14 items. Evaluation of the model with 10 to 17 variables was performed to ensure that the model with the 14 items met the most criteria for fit with the PCA, the receiver operating characteristic (ROC) curve, and the IRT modeling criteria. The responsiveness (sensitivity and specificity) of the change scores in the shortened 14-item survey, the 30-item TESS LE, and the 20-item LEFS as compared with the dichotomized changes in Item 3 of the PROMIS global health tool was evaluated using ROCs. The concordance (accuracy and precision) of the 14 items derived from the LEFS and TESS LE was evaluated. RESULTS: The responsiveness (sensitivity and specificity) of the shortened 14-item survey, the TESS LE, and the LEFS to the criterion target of the PROMIS global health tool (Item 3) was similar, with areas under the curve (AUCs) ranging from 0.62 to 0.65 for the ROC curves. The responsiveness of the 14-item survey to the TESS LE showed sensitivity of 96% and specificity of 90%, with an AUC of 0.98 (p < 0.001). The responsiveness of the 14 items to the LEFS showed sensitivity of 95% and specificity of 86%, with an AUC of 0.96. The validity of the 14 items to the TESS LE was measured by concordance, with a precision of 0.98 and an accuracy of 0.97. Concordance of the 14 items to the LEFS showed a precision of 0.98 and accuracy of 0.83. CONCLUSION: The concise 14 items derived from patient-reported responses in the TESS LE and LEFS outcome measures showed similar responsiveness (sensitivity and specificity) as the original TESS LE and LEFS for cancer patients after lower extremity orthopaedic surgery performed for oncologic and nononcologic indications. The concise 14 items have a similar ability to the TESS LE and LEFS to tell the clinician or patient how they are functioning compared with other patients. These 14 items are shorter than the combined 50 items of the TESS LE and LEFS while retaining the capacity to describe a broad range of lower extremity function for orthopaedic oncology patients. We have named the 14-item survey the Lower Extremity Oncology Functional Assessment Tool (LEO).Level of Evidence Level II, diagnostic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Nalty T, Patel SS, Bird JE, et al. Does a Concise Patient-reported Outcome Measure Provide a Valid Measure of Physical Function for Cancer Patients After Lower Extremity Surgery? Clin Orthop Relat Res. 2024. PMID: 39387488. doi:10.1097/CORR.0000000000003257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。